These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 19636696

  • 21. Condoms, Lubricants and Rectal Cleansing: Practices Associated with Heterosexual Penile-Anal Intercourse Amongst Participants in an HIV Prevention Trial in South Africa, Uganda and Zimbabwe.
    Duby Z, Hartmann M, Montgomery ET, Colvin CJ, Mensch B, van der Straten A.
    AIDS Behav; 2016 Apr; 20(4):754-62. PubMed ID: 26126586
    [Abstract] [Full Text] [Related]

  • 22. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
    Carballo-Diéguez A, Balán IC, Morrow K, Rosen R, Mantell JE, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K.
    AIDS Care; 2007 Sep; 19(8):1026-31. PubMed ID: 17852000
    [Abstract] [Full Text] [Related]

  • 23. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J, Mwethera PG, Wiysonge CS.
    Cochrane Database Syst Rev; 2012 Jun 13; (6):CD007961. PubMed ID: 22696373
    [Abstract] [Full Text] [Related]

  • 24. The role of partnership dynamics in determining the acceptability of condoms and microbicides.
    Montgomery CM, Lees S, Stadler J, Morar NS, Ssali A, Mwanza B, Mntambo M, Phillip J, Watts C, Pool R.
    AIDS Care; 2008 Jul 13; 20(6):733-40. PubMed ID: 18576176
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Reformulated tenofovir gel for use as a dual compartment microbicide.
    Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, Cost M, Lynam JD, Friend D.
    J Antimicrob Chemother; 2012 Sep 13; 67(9):2139-42. PubMed ID: 22581908
    [Abstract] [Full Text] [Related]

  • 28. Women's interest in vaginal microbicides.
    Darroch JE, Frost JJ.
    Fam Plann Perspect; 1999 Sep 13; 31(1):16-23. PubMed ID: 10029928
    [Abstract] [Full Text] [Related]

  • 29. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
    Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M, CAPRISA004 Trial Group.
    J Acquir Immune Defic Syndr; 2012 Jun 01; 60(2):124-7. PubMed ID: 22362152
    [Abstract] [Full Text] [Related]

  • 30. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW.
    AIDS Behav; 2013 Feb 01; 17(2):737-47. PubMed ID: 23065145
    [Abstract] [Full Text] [Related]

  • 31. 'The study has taught me to be supportive of her': empowering women and involving men in microbicide research.
    Venables E, Stadler J.
    Cult Health Sex; 2012 Feb 01; 14(2):181-94. PubMed ID: 22085043
    [Abstract] [Full Text] [Related]

  • 32. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
    Hart CW, Joanis C, Hartmann M, Milford C, Smit J, Beksinska M, Rambally-Greener L, Pienaar J, Mabude Z, Butterworth GAM, Sokal D, Jenkins D.
    Eur J Contracept Reprod Health Care; 2019 Oct 01; 24(5):390-398. PubMed ID: 31517545
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
    Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, Ngcobo N, Abdool Karim SS, Abdool Karim Q.
    AIDS Behav; 2014 May 01; 18(5):849-54. PubMed ID: 24633715
    [Abstract] [Full Text] [Related]

  • 35. The role of men in women's acceptance of an intravaginal gel in a randomized clinical trial in Blantyre, Malawi: a qualitative and quantitative analysis.
    Salter ML, Go VF, Celentano DD, Diener-West M, Nkhoma CM, Kumwenda N, Taha TE.
    AIDS Care; 2008 Aug 01; 20(7):853-62. PubMed ID: 18608053
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties.
    Morrow KM, Fava JL, Rosen RK, Vargas S, Barroso C, Christensen AL, Woodsong C, Severy L.
    J Acquir Immune Defic Syndr; 2007 May 01; 45(1):93-101. PubMed ID: 17325607
    [Abstract] [Full Text] [Related]

  • 39. Adolescents' and young women's use of a microbicide surrogate product when receiving oral sex.
    Auslander BA, Catallozzi M, Davis G, Succop PA, Stanberry LR, Rosenthal SL.
    J Pediatr Adolesc Gynecol; 2014 Feb 01; 27(1):37-40. PubMed ID: 24315715
    [Abstract] [Full Text] [Related]

  • 40. Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
    Baxter C, Yende-Zuma N, Tshabalala P, Abdool Karim Q, Abdool Karim SS.
    Antiviral Res; 2013 Sep 01; 99(3):405-8. PubMed ID: 23832086
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.